Safety concerns were front and center at Thursday's meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) reviewing Titan Pharmaceuticals Inc.'s application for Probuphine, an implantable device delivering a steady dose of buprenorphine for up to six months for opioid dependence.